Beam TherapeuticsBEAM
Recorded

Beam Therapeutics UBS Global Biopharma Conference 2026

Review the key takeaways and the transcript of this earnings call.

Period 2026Duration31 minParticipants2

Transcript

Preview the first fifteen paragraphs, organized by speaker.

Michael YeeAnalyst

All right. All right. Well, good afternoon, everyone. Thank you for joining us. I hope everyone had a great lunch here at the UBS Global Biopharma Conference. I'm Michael Yee, Global Head of Biotech Research here at UBS. Really pleased to have on stage with us Beam Therapeutics, Chief Executive Officer John Evans. Thank you so much for being here with us.

John EvansCEO

Great to be here. Thank you.

Michael YeeAnalyst

Fantastic. Beam has had an exciting year. You've been reporting a lot of data across not only your lead program, sickle cell, which just had an update, but also across the AAT program, and also some early data across GSD1a too. Let's talk about some of that. Maybe if I could just offer you an opportunity to make some opening comments. Where are you with these three programs, and what are the next key milestones as you think about some of these key programs?

John EvansCEO

Great. Yeah. Thank you for having me again, and we are having a very exciting year. I think this is the year when the full potential of this platform that we've been building is now really visible.

John EvansCEO

Yeah. Particularly the fact that it is a platform technology.

John EvansCEO

This is base editing, where we are going to fix single letters in genes to correct for mutations, and it is delivery that is very well validated at this point, whether it be an ex vivo transplant or a lipid nanoparticle. Once those begin to work, they keep working, and we have every reason to believe that the next version of that technology, the next time we put it into patients, different disease, we should get the same positive result, and we are starting to see that now. So across those programs, with sickle cell disease, as you noted, we just had the top line data, just top line release, but it is positive, so that is great. That keeps us on track for a BLA filing, as early as December. So we are hard at work right now on that.

John EvansCEO

We can talk a lot more about that, but very exciting, highly differentiated program for patients with sickle cell disease.

Michael YeeAnalyst

You are hosting something at ASH, I think, too.

John EvansCEO

Yes. Yep. That is going to be a nice event. Yep, absolutely. With alpha-1, of course, very high-profile disease where we have a really significant leadership position. First time ever in medical history to actually correct a broken mutation back to normal and get these patients to what looks like it should be a functional cure. There, it is all about how fast we are going. We have an incredible global site network now, and we have announced that we started dosing in July. We will be finished dosing the 50 patients in that trial by the first half of next year.

John EvansCEO

It is moving really quickly. Then we follow them for a year, and then that is the data set that we can use to file. That is really, really exciting. Then, as you noted, there is sort of a third leg of the stool for Beam, which is our metabolic sort of profile franchise. We have a program on PKU that will be dosing in early 2027. Then BEAM-301 for glycogen storage disease 1a, we just had its first clinical proof of concept data. Here, really dramatic results showing in some of these patients, reduction of cornstarch utilization and actually freedom from cornstarch in a couple of situations, and ability to fast. It is something that these patients just cannot do without going hypoglycemic.

Michael YeeAnalyst

It is basically a functional cure in an ultra-rare population.

John EvansCEO

Correct. Yeah. Very, very exciting for that population, and then more broadly, kind of speaks to what should be possible in PKU and in many other disorders of the liver, where we should be able to now reliably deliver the base editor, reliably fix the mutation, and that really should be a functional cure for- Might I add, the latter two programs are in vivo as well.

John EvansCEO

That's right. Yes, of all of those, the only one is ex vivo is sickle. Our LNP and mRNA capabilities are quite significant. From alpha-1 through PKU and GSD, it's all in vivo, which means two- to three-hour infusion and off you go.

Michael YeeAnalyst

One and done in two to three hours.

Michael YeeAnalyst

That's right. Let's start with sickle cell.

FULL TRANSCRIPT

Continue the full translated transcript in StockNow.

Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.

View the full transcript with Pro

Other earnings calls that day

View calls from this day